These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 27552450)

  • 1. Current and Future Stem Cell Regulation: A Call to Action.
    Anz A
    Am J Orthop (Belle Mead NJ); 2016; 45(5):274-318. PubMed ID: 27552450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular Therapies in Orthopedics: Where Are We?
    Piuzzi NS; Khlopas A; Sodhi N; Oak S; Sultan AA; Chughtai M; Mantripragada VP; Mont MA; Muschler GF
    Surg Technol Int; 2017 Dec; 31():359-364. PubMed ID: 29316595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA regulation of adult stem cell therapies as used in sports medicine.
    Chirba MA; Sweetapple B; Hannon CP; Anderson JA
    J Knee Surg; 2015 Feb; 28(1):55-62. PubMed ID: 25603042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stem Cells in Orthopedics: A Comprehensive Guide for the General Orthopedist.
    Saltzman BM; Kuhns BD; Weber AE; Yanke A; Nho SJ
    Am J Orthop (Belle Mead NJ); 2016; 45(5):280-326. PubMed ID: 27552451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unproven stem cell-based interventions and achieving a compromise policy among the multiple stakeholders.
    Matthews KR; Iltis AS
    BMC Med Ethics; 2015 Nov; 16(1):75. PubMed ID: 26537611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
    Knoepfler PS
    Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
    von Tigerstrom B
    Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allograft update: the current status of tissue regulation, procurement, processing, and sterilization.
    McAllister DR; Joyce MJ; Mann BJ; Vangsness CT
    Am J Sports Med; 2007 Dec; 35(12):2148-58. PubMed ID: 17974862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2005 Donor Eligibility Requirements: Unintended Consequences for Stem Cell Development.
    Couture LA; Carpenter MK
    Stem Cells Transl Med; 2015 Oct; 4(10):1097-100. PubMed ID: 26285658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of medical devices in radiology: current standards and future opportunities.
    Smith JJ
    Radiology; 2001 Feb; 218(2):329-35. PubMed ID: 11161144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory crackdown on stem cell therapy: what would the position be in South Africa?
    Jordaan D
    S Afr Med J; 2012 Mar; 102(4):219-20. PubMed ID: 22464500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA regulation of stem cell-based products.
    Fink DW
    Science; 2009 Jun; 324(5935):1662-3. PubMed ID: 19556496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing Induced Pluripotent Stem Cell-Based Therapy for the Masses.
    Rao MS; Atala A
    Stem Cells Transl Med; 2016 Feb; 5(2):129-31. PubMed ID: 26718646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current regulatory issues in cell and tissue therapy.
    Burger SR
    Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA regulation of stem-cell-based therapies.
    Halme DG; Kessler DA
    N Engl J Med; 2006 Oct; 355(16):1730-5. PubMed ID: 17050899
    [No Abstract]   [Full Text] [Related]  

  • 19. Are stem cells drugs? The regulation of stem cell research and development.
    Rosen MR
    Circulation; 2006 Oct; 114(18):1992-2000. PubMed ID: 17075025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A drug's life: the pathway to drug approval.
    Keng MK; Wenzell CM; Sekeres MA
    Clin Adv Hematol Oncol; 2013 Oct; 11(10):646-55. PubMed ID: 24518374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.